Inhibition of adrenaline-induced platelet aggregation by the alpha-adrenoceptor blocking drug benextramine.
1 The activity of the irreversible alpha-adrenoceptor blocking drug, benextramine, was determined in human platelets. 2 Compared to its postsynaptic and presynaptic alpha-adrenoceptor blocking potency, benextramine had a very low potency as an antagonist of adrenaline-induced platelet aggregation. 3 The results confirm the previous observation with the irreversible alpha-adrenoceptor blocking drug, phenoxybenzamine, that platelet alpha-adrenoceptors differ from postsynaptic and presynaptic alpha-adrenoceptors.
D000244:Adenosine Diphosphate / Q000037:antagonists & inhibitors; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology*; D003094:Collagen / Q000037:antagonists & inhibitors; D003538:Cystamine / Q000031:analogs & derivatives* / Q000494:pharmacology; D004837:Epinephrine / Q000037:antagonists & inhibitors*; D006801:Humans; D010646:Phentolamine / Q000494:pharmacology; D010974:Platelet Aggregation / Q000187:drug effects*; D011802:Quinidine / Q000494:pharmacology; D014700:Verapamil / Q000494:pharmacology
D000317:Adrenergic alpha-Antagonists; D000244:Adenosine Diphosphate; C029998:benextramine; D003094:Collagen; D014700:Verapamil; D011802:Quinidine; D003538:Cystamine; D004837:Epinephrine; D010646:Phentolamine